Heather Lochnan

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 2.8K citations · Full text

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +9

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 600 citations · Full text

Metabolic Syndrome, Diabetes Management, Urology +10

Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial

John R. Petrie, Nish Chaturvedi, Ian Ford et al. · The Lancet Diabetes & Endocrinology · 2017 · 337 citations · Full text

Metabolic Syndrome, Type 1, Diabetes Management +7

Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial

Hertzel C. Gerstein, Michael E. Miller, Faramarz Ismail‐Beigi et al. · The Lancet · 2014 · 151 citations

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +12

Deprescribing antihyperglycemic agents in older persons: Evidence-based clinical practice guideline.

Barbara Farrell, Cody Black, Wade Thompson et al. · PubMed · 2017 · 145 citations